Mary E. Brunkow, PhD, Fred Ramsdell, PhD, and Shimon Sakaguchi, MD, PhD, have been awarded the Nobel Prize in Physiology or Medicine 2025 for their groundbreaking discoveries concerning peripheral immune tolerance that prevents the immune system from harming the body.
Researchers at La Jolla Institute for Immunology and Columbia University Irving Medical Center have discovered that amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, may be an autoimmune disorder.
A University of Toledo immunologist has received a federal grant to study how a type of cell unexpectedly discovered in the oral cavity helps the body fight off fungal infections.
A groundbreaking retrospective cohort analysis of more than four million children conducted at Sungkyunkwan University in South Korea offers compelling evidence that there is no significant association between early antibiotic exposure and heightened risk of autoimmune diseases in children.
A new study reveals lymphoma can accelerate the biological aging of the immune system and other tissues.
The National Institutes of Health announced a significant change to the terms and conditions governing federal funding applicable to all NIH grants, cooperative agreements and other awards, including future awards.
Early clinical and preclinical results are showing that an experimental mRNA and nanoparticle vaccine produced measurable immune responses against pancreatic cancer, and that in small patient groups, those immune responses correlated with delayed recurrence or prolonged survival.
The U.S. Department of Health and Human Services has reinstated the Task Force on Safer Childhood Vaccines, a long-dormant federal panel created by Congress to oversee the safety and quality of children’s vaccines.
The U.S. Food and Drug Administration is requiring safety labeling changes to all opioid pain medications to better emphasize and explain the risks associated with their long-term use.
Argenx is conducting a Phase IV clinical study to evaluate how adults with chronic inflammatory demyelinating polyneuropathy transition from intravenous immune globulin treatment to efgartigimod PH20 SC.
The U.S. Department of Health and Human Services (HHS) has begun a coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA).
The U.S. Food and Drug Administration has granted fast track designation for Greenwich LifeSciences’ lead immunotherapy candidate GLSI-100 in HLA-A*02–positive, HER2-positive breast cancer patients who have completed standard HER2-targeted therapy.